Skip to Main Content

INFORMATION FOR

James Farrell, MBChB

Professor of Medicine (Digestive Diseases); Director, Yale Center for Pancreatic Diseases

Research Summary

Dr James Farrell is focussed on research into early diagnosis of pancreatic cancer through studying high risk groups such as those with a strong family history of pancreatic cancer or inherited susceptibility genes, new onset diabetes and pancreatic cystic neoplasms. In addition he pursues novel approaches to the management of pancreatic cancer, including novel diagnostic and precision medicine approaches.

Extensive Research Description

Dr James Farrell has leveraged his clinical expertise and activities as a practicing clinical gastroenterologist, board certified clinical pharmacologist, and interventional endoscopist to create a successful clinical and translational research program focused on pancreatic cancer in the areas of early pancreatic cancer diagnosis, pancreatic cystic neoplasms and pancreatic cancer therapeutics and pharmacogenomics.

1. Early Diagnosis of Pancreatic Cancer

In addition to studying potential salivary transcriptomic and bacterial biomarkers for early detection in pancreatic cancer, he was the UCLA-PI for CAPS3, the Yale_PI for CAPS5, large prospective multicenter pancreatic cancer screening studies in at-risk individuals based on family history of pancreatic cancer and/or inherited germline mutations ( e.g. BRCA2), the Yale_PI for PanFAM1, a prospective biomarker analysis of high risk individuals, and a member of the International Pancreatic Cancer Screening and PRECEDE Consortia.

2. Pancreatic Cystic Neoplasms

Dr Farrell’s clinical and translational research work in the field of pancreatic cystic neoplasms has ranged from studies validating current clinical guidelines, to the development of clinically useful nomograms for patients with pancreatic cysts, to studies aimed at identifying novel pancreatic cyst fluid proteomic and microRNA biomarkers. To this end, he initiated and maintain a pancreatic cyst fluid research biobank (2001 to present) which has now over 400 patient pancreatic cyst fluid specimens with clinical and pathologic correlation. Currently he serves as the Yale PI for ECOG-ACRIN 2185, A Randomized Controlled Clinical Trial studying surveillance practices for individuals with Pancreatic Cysts.

3. Pancreatic Cancer Therapeutics and Personalized Medicine

Dr Farrell’s work in the field of pancreatic cancer therapeutics has included exploration of Endoscopic ultrasound guided tumor injection with gene therapy as well as the development and validation of treatment predictive pharmacogenomic markers in pancreatic cancer. In addition to his work looking at SNPs as predictive markers of treatment response and toxicity, in collaboration with the RTOG Co-operative trials group, he validated hENT1 (human equilibrative nucleoside transporter 1) as a predictive marker of gemcitabine responsivity in pancreatic cancer. This has directly led to the development of a commercially available hENT1 based tissue assay and the first hENT1 biomarker driven multicenter treatment trial in pancreatic cancer.

Coauthors

Research Interests

Barrett Esophagus; Bile Duct Neoplasms; Cholestasis, Extrahepatic; Biliary Tract Diseases; Biliary Tract Neoplasms; Cholangitis; Cholecystitis; Cholelithiasis; Cholestasis; Cholestasis, Intrahepatic; Colonic Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Common Bile Duct Diseases; Common Bile Duct Neoplasms; Digestive System Abnormalities; Digestive System Diseases; Digestive System Neoplasms; Duodenal Neoplasms; Esophageal Cyst; Esophageal Diseases; Esophageal Fistula; Esophageal Neoplasms; Gallbladder Diseases; Gastric Fistula; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Glucagonoma; Ileal Neoplasms; Intestinal Neoplasms; Pancreatic Cyst; Pancreatic Diseases; Pancreatic Fistula; Exocrine Pancreatic Insufficiency; Pancreatic Neoplasms; Pancreatic Pseudocyst; Rectal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Cholangitis, Sclerosing; Gastrinoma; Choledochal Cyst; Carcinoma, Pancreatic Ductal; Cholecystolithiasis; Cholecystitis, Acute; Emphysematous Cholecystitis; Gallstones; Choledocholithiasis; Gastrointestinal Stromal Tumors

Public Health Interests

Biomarkers; Cancer

Selected Publications

  • SURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVALBlackford A, Canto M, Dbouk M, Kerdsirichairat T, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Stoffel E, Syngal S, Klein A, Hruban R, Goggins M. SURVEILLANCE OF HIGH-RISK INDIVIDUALS LEADS TO LOWER STAGE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AT DIAGNOSIS AND IMPROVED OVERALL AND DISEASE-SPECIFIC SURVIVAL Gastrointestinal Endoscopy 2022, 95: ab544-ab545. DOI: 10.1016/j.gie.2022.04.1334.
  • The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer.Zogopoulos G, Bi Y, Brand R, Chung D, Earl J, Farrell J, Graff J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Permuth J, Sears R, Simeone D. The PRECEDE consortium: A longitudinal international cohort study of individuals with genetic risk or familial pancreatic cancer. Journal Of Clinical Oncology 2022, 40: e16239-e16239. DOI: 10.1200/jco.2022.40.16_suppl.e16239.
  • Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMSChhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.
  • Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSISSingh S, Chhoda A, Vodusek Z, Khatri R, Gunderson C, McCarty T, Sharma P, Grimshaw A, Kunstman J, Sharma A, Ahuja N, Gonda T, Farrell J. Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS Gastroenterology 2022, 162: s-907. DOI: 10.1016/s0016-5085(22)62148-6.
  • 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASEKhatri R, Chhoda A, Sharma A, Farrell J, Ahuja N, Ehrlich A, Friedenberg F. 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE Gastroenterology 2022, 162: s-270-s-271. DOI: 10.1016/s0016-5085(22)60641-3.
  • 1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORTDbouk M, Chak A, Brand R, Farrell J, Kastrinos F, Katona B, Rustgi A, Kwon R, Stoffel E, Syngal S, Shin E, Canto M, Goggins M. 1061: PANCREATIC CANCER STAGE IN THE MULTICENTER CANCER OF THE PANCREAS SCREENING COHORT Gastroenterology 2022, 162: s-242-s-243. DOI: 10.1016/s0016-5085(22)60577-8.
  • Abstract PO-155: Racial heterogeneity in the molecular landscape of pancreatic adenocarcinoma: A call for actionLarson H, Chhoda A, Hengartner A, Hasan N, Ruzgar N, Yalamanchi S, Kunstman J, Farrell J, Sharma A, Ahuja N. Abstract PO-155: Racial heterogeneity in the molecular landscape of pancreatic adenocarcinoma: A call for action Cancer Epidemiology Biomarkers & Prevention 2022, 31: po-155-po-155. DOI: 10.1158/1538-7755.disp21-po-155.
  • S1030 Prevalence and Predictors of Musculoskeletal Disorders Amongst Nurses and Technicians Assisting in ERCPMbachi C, Jamidar P, Muniraj T, Farrell J, , Campbell E, Aslanian H. S1030 Prevalence and Predictors of Musculoskeletal Disorders Amongst Nurses and Technicians Assisting in ERCP The American Journal Of Gastroenterology 2021, 116: s489-s489. DOI: 10.14309/01.ajg.0000777652.16974.b4.
  • ID: 3524866 ENDOSCOPIC ULTRASOUND - FINE NEEDLE BIOPSY (EUS-FNB) DERIVED HUMAN ORGANOID MODELS IN PANCREATIC CANCER: CLINICAL AND TECHNICAL PREDICTORS OF SUCCESSYoo J, Nair G, Shorr E, LaComb J, Kesar V, Foster G, Joshi N, Farrell J, Buscaglia J. ID: 3524866 ENDOSCOPIC ULTRASOUND - FINE NEEDLE BIOPSY (EUS-FNB) DERIVED HUMAN ORGANOID MODELS IN PANCREATIC CANCER: CLINICAL AND TECHNICAL PREDICTORS OF SUCCESS Gastrointestinal Endoscopy 2021, 93: ab247-ab248. DOI: 10.1016/j.gie.2021.03.535.
  • ID: 3527197 ENDOSCOPIC ULTRASOUND SHEAR WAVE ELASTOGRAPHY (SWE) FOR HIGH RISK INDIVIDUAL PANCREATIC CANCER SURVEILLANCE: A PILOT STUDYChhoda A, Merenda S, Farrell J. ID: 3527197 ENDOSCOPIC ULTRASOUND SHEAR WAVE ELASTOGRAPHY (SWE) FOR HIGH RISK INDIVIDUAL PANCREATIC CANCER SURVEILLANCE: A PILOT STUDY Gastrointestinal Endoscopy 2021, 93: ab262-ab263. DOI: 10.1016/j.gie.2021.03.561.
  • ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDYNair G, Yoo J, Vanella G, Angeletti S, Mauro A, Zingone F, Toma A, Pouillon L, Papanikolaou I, Boskoski I, Bronswijk M, Capurso G, Dilaghi E, Di Sabatino A, Savarino E, Fracasso P, Matteo M, Van Der Merwe S, Petrone M, Di Giulio E, Roelandt P, Arcidiacono P, Costamagna G, Farrell J. ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDY Gastrointestinal Endoscopy 2021, 93: ab45-ab46. PMCID: PMC8149182, DOI: 10.1016/j.gie.2021.03.152.
  • Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE.Chhoda A, Singh S, Sheth A, Sharma P, Sharma A, Kunstman J, Grimshaw A, Ahuja N, Farrell J. Sa298 IS IT SAFE TO STOP SURVEILLANCE OF PANCREATIC CYSTS AFTER 5 YEARS OF STABILITY?: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CURRENT EVIDENCE. Gastroenterology 2021, 160: s-475. DOI: 10.1016/s0016-5085(21)01841-2.
  • Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSISChhoda A, Singh S, Grimshaw A, Sheth A, Sharma A, Kunstman J, Ahuja N, Farrell J. Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS Gastroenterology 2021, 160: s-477. DOI: 10.1016/s0016-5085(21)01845-x.
  • Sa293 ASSESSMENT OF PROGRESSION OF CHRONIC PANCREATITIS-LIKE LESIONS IN HIGH RISK INDIVIDUALS UNDERGOING PANCREATIC CANCER SURVEILLANCEChhoda A, Merenda S, Farrell J. Sa293 ASSESSMENT OF PROGRESSION OF CHRONIC PANCREATITIS-LIKE LESIONS IN HIGH RISK INDIVIDUALS UNDERGOING PANCREATIC CANCER SURVEILLANCE Gastroenterology 2021, 160: s-473-s-474. DOI: 10.1016/s0016-5085(21)01836-9.
  • Sa297 COMPLIANCE APPRAISAL OF A TAILORED PRECISION MEDICINE APPROACH IN A HIGH-RISK PANCREATIC CANCER SURVEILLANCE PROGRAMChhoda A, Merenda S, Farrell J. Sa297 COMPLIANCE APPRAISAL OF A TAILORED PRECISION MEDICINE APPROACH IN A HIGH-RISK PANCREATIC CANCER SURVEILLANCE PROGRAM Gastroenterology 2021, 160: s-474-s-475. DOI: 10.1016/s0016-5085(21)01840-0.
  • Cystic Tumors Other than IPMNKunstman J, Farrell J. Cystic Tumors Other than IPMN 2021, 608-623. DOI: 10.1002/9781119570097.ch74.
  • S0106 Imaging Resource Utilization in the Surveillance of Presumed Branched Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN)Yousaf M, Zhang Z, Chhoda A, Madhani K, Chaudhary F, Suarez A, Muniraj T, Kunstman J, Jamidar P, Aslanian H, Salem R, Farrell J. S0106 Imaging Resource Utilization in the Surveillance of Presumed Branched Duct Intraductal Papillary Mucinous Neoplasm (BD-IPMN) The American Journal Of Gastroenterology 2020, 115: s51-s51. DOI: 10.14309/01.ajg.0000702472.90174.1c.
  • S0116 Balancing Risks of Pancreatic Malignancy-Related and Non-Pancreatic-Related Mortality in Surveillance of Low-Risk Presumed Mucinous Pancreatic CystsChhoda A, Madhani K, Yousuf M, Aslanian H, Jamidar P, Kunstman J, Salem R, Suarez A, Farrell J. S0116 Balancing Risks of Pancreatic Malignancy-Related and Non-Pancreatic-Related Mortality in Surveillance of Low-Risk Presumed Mucinous Pancreatic Cysts The American Journal Of Gastroenterology 2020, 115: s56-s57. DOI: 10.14309/01.ajg.0000702512.87644.ef.
  • Su1484 VALIDATION OF BASELINE CHARLSON COMORBIDITY INDEX (CACI) IN PREDICTING SURVIVAL IN A PANCREAS CYST SURVEILLANCE COHORT: AN INTERIM ANALYSISChhoda A, Madhani K, Yousaf M, Aslanian H, Jamidar P, Muniraj T, Suarez A, Salem R, Farrell J. Su1484 VALIDATION OF BASELINE CHARLSON COMORBIDITY INDEX (CACI) IN PREDICTING SURVIVAL IN A PANCREAS CYST SURVEILLANCE COHORT: AN INTERIM ANALYSIS Gastroenterology 2020, 158: s-598. DOI: 10.1016/s0016-5085(20)32198-3.
  • Sa1154 ORGANOID-BASED PRECLINICAL MODELS RECAPITULATE RENALASE SIGNALING IN PANCREATIC DUCTAL ADENOCARCINOMANair G, Yoo J, Gao Y, Desir G, Gorelick F, Farrell J, Foster G, Joshi N. Sa1154 ORGANOID-BASED PRECLINICAL MODELS RECAPITULATE RENALASE SIGNALING IN PANCREATIC DUCTAL ADENOCARCINOMA Gastroenterology 2020, 158: s-293. DOI: 10.1016/s0016-5085(20)31426-8.
  • Su1159 FACTORS ASSOCIATED WITH “MISSED CANCERS” IN PROSPECTIVE HIGH-RISK PANCREAS CANCER SURVEILLANCE PROGRAMS. ROOM FOR IMPROVEMENT?Chhoda A, Wattamwar K, Kastrinos F, Farrell J. Su1159 FACTORS ASSOCIATED WITH “MISSED CANCERS” IN PROSPECTIVE HIGH-RISK PANCREAS CANCER SURVEILLANCE PROGRAMS. ROOM FOR IMPROVEMENT? Gastroenterology 2020, 158: s-528. DOI: 10.1016/s0016-5085(20)32008-4.
  • Su1486 LONG-TERM SURVEILLANCE OF LOW-RISK PRESUMED MUCINOUS CYSTS: A SYSTEMATIC REVIEW AND META-ANALYSISChhoda A, singh S, Sheth A, Grimshaw A, Farrell J. Su1486 LONG-TERM SURVEILLANCE OF LOW-RISK PRESUMED MUCINOUS CYSTS: A SYSTEMATIC REVIEW AND META-ANALYSIS Gastroenterology 2020, 158: s-599. DOI: 10.1016/s0016-5085(20)32200-9.
  • Su1147 PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PATIENT-DERIVED TUMOR ORGANOID (PDTO) GENERATION BY EUS-FNB IS FEASIBLE IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPYYoo J, Nair G, Kesar V, Foster G, Joshi N, Farrell J. Su1147 PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) PATIENT-DERIVED TUMOR ORGANOID (PDTO) GENERATION BY EUS-FNB IS FEASIBLE IN PATIENTS PREVIOUSLY TREATED WITH CHEMOTHERAPY Gastroenterology 2020, 158: s-524. DOI: 10.1016/s0016-5085(20)31997-1.
  • Pancreatic Cancer; Biomolecular and Genetic AspectsYoo J, Farrell J. Pancreatic Cancer; Biomolecular and Genetic Aspects 2020, 30-38. DOI: 10.1016/b978-0-12-801238-3.65864-6.
  • 67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-AnalysisChhoda A, Mukherjee E, Wattamwar K, Kastrinos F, Farrell J. 67 Appraisal of Follow-up Protocols and Outcomes of High Risk Pancreatic Cancer Surveillance Programs: A Systematic Review and Meta-Analysis The American Journal Of Gastroenterology 2019, 114: s40-s41. DOI: 10.14309/01.ajg.0000589800.17291.ef.
  • The Expanding Role of Endoscopy in Tissue Acquisition and Therapeutic Interventions for Gastrointestinal and Neuroendocrine MalignanciesFarrell J. The Expanding Role of Endoscopy in Tissue Acquisition and Therapeutic Interventions for Gastrointestinal and Neuroendocrine Malignancies 2019, 533-550. DOI: 10.1007/978-3-030-18890-0_30.
  • Updated international Cancer of the Pancreas Screening (CAPS) consortium guidelines on the management of patients with increased risk for familial pancreatic cancerOverbeek K, Canto M, Bartsch D, Brand R, Carrato A, Del Chiaro M, Farrell J, Fishman E, Fockens P, Gress T, van Hooft J, Kastrinos F, Rustgi A, Syngal S, Vasen H, Cahen D, Bruno M, Goggins M, Consortium I. Updated international Cancer of the Pancreas Screening (CAPS) consortium guidelines on the management of patients with increased risk for familial pancreatic cancer Pancreatology 2019, 19: s56-s57. DOI: 10.1016/j.pan.2019.05.143.
  • Su1459 – Imaging Resource Utilization in Active Pancreatic Cyst SurveillanceYousaf M, Zhang Z, Chhoda A, Madhani K, Suarez A, Muniraj T, Kunstman J, Jamidar P, Aslanian H, Salem R, Farrell J. Su1459 – Imaging Resource Utilization in Active Pancreatic Cyst Surveillance Gastroenterology 2019, 156: s-559. DOI: 10.1016/s0016-5085(19)38287-3.
  • Sa1350 – Updated International Cancer of the Pancreas Screening (CAPS) Consortium Guidelines on the Management of Patients with Increased Risk for Familial Pancreatic CancerOverbeek K, Canto M, Bartsch D, Brand R, Carrato A, Del Chiaro M, Farrell J, Fishman E, Fockens P, Gress T, van Hooft J, Kastrinos F, Rustgi A, Syngal S, Vasen H, Cahen D, Bruno M, Goggins M. Sa1350 – Updated International Cancer of the Pancreas Screening (CAPS) Consortium Guidelines on the Management of Patients with Increased Risk for Familial Pancreatic Cancer Gastroenterology 2019, 156: s-323. DOI: 10.1016/s0016-5085(19)37637-1.
  • Comorbidity Burden in Active Pancreatic Cyst Surveillance PopulationChhoda A, Yousaf M, Madhani K, Harry A, Jamidar P, Muniraj T, Salem R, Suarez A, Farrell J. Comorbidity Burden in Active Pancreatic Cyst Surveillance Population The American Journal Of Gastroenterology 2018, 113: s30. DOI: 10.14309/00000434-201810001-00048.
  • Sa1375 - Risk of Malignancy in Pancreatic Cystic Lesions Triaged by Clinical and Molecular FeaturesGonda T, Al-Haddad M, Jackson S, Toney N, Farrell J. Sa1375 - Risk of Malignancy in Pancreatic Cystic Lesions Triaged by Clinical and Molecular Features Gastroenterology 2018, 154: s-283-s-284. DOI: 10.1016/s0016-5085(18)31306-4.
  • P-LUM-06: Diagnostic accuracy of combined needle use of the new 20-gauge procore fine needle biopsy and the 25-gauge fine needle aspiration needle in solid gastrointestinal lesionsvan Riet P, Arcidiacono P, Petrone M, Dabizzi E, Nguyen N, Kitano M, Chang K, van der Merwe S, Bruno M, Cahen D, Larghi A, Iglesias-Garcia J, Giovannini M, Santo E, Silva F, Bucobo J, Robert M, Adeniran A, Celli R, Aslanian H, Farrell J. P-LUM-06: Diagnostic accuracy of combined needle use of the new 20-gauge procore fine needle biopsy and the 25-gauge fine needle aspiration needle in solid gastrointestinal lesions Endoscopic Ultrasound 2017, 6: s12-s12. PMCID: PMC5569758, DOI: 10.4103/2303-9027.212309.
  • Advanced Endoscopic ProceduresFarrell J. Advanced Endoscopic Procedures 2017, 151-169. DOI: 10.1007/978-3-319-58256-6_8.
  • Su1353 Diagnostic Accuracy of Combined Needle Use of the New 20G Procore Fnb and the 25G Fna Needle in Solid Gi-Lesionsvan Riet P, Arcidiacono P, Petrone M, Dabizzi E, Nguyen N, Kitano M, Chang K, Van Der Merwe S, Bruno M, Cahen D, Larghi A, Iglesias-Garcia J, Giovannini M, Santo E, Silva F, Bucobo J, Robert M, Adeniran A, Celli R, Aslanian H, Farrell J. Su1353 Diagnostic Accuracy of Combined Needle Use of the New 20G Procore Fnb and the 25G Fna Needle in Solid Gi-Lesions Gastrointestinal Endoscopy 2017, 85: ab347. DOI: 10.1016/j.gie.2017.03.799.
  • Su1348 The Impact of Endoscopic Ultrasound on Diagnosis and Management of Presumed Mucinous Neoplasms When Done for Pancreatic Cyst Morphology Change on Non-Invasive Surveillance ImagingMadhani K, Yousaf M, Aamar A, Ooka K, Aslanian H, Salem R, Farrell J. Su1348 The Impact of Endoscopic Ultrasound on Diagnosis and Management of Presumed Mucinous Neoplasms When Done for Pancreatic Cyst Morphology Change on Non-Invasive Surveillance Imaging Gastrointestinal Endoscopy 2017, 85: ab344-ab345. DOI: 10.1016/j.gie.2017.03.794.
  • Mo1095 DNA Analysis of Pancreatic Cystic Fluid Has Incremental Predictive Value in Assessing Future Risk of Malignant OutcomesGonda T, Jackson S, Toney N, Farrell J. Mo1095 DNA Analysis of Pancreatic Cystic Fluid Has Incremental Predictive Value in Assessing Future Risk of Malignant Outcomes Gastrointestinal Endoscopy 2017, 85: ab425. DOI: 10.1016/j.gie.2017.03.987.
  • 1125 Cryoablation of a Duodenal Adenoma With Invasive Carcinoma Refractory to Endoscopic Mucosal Resection, Radiofrequency Ablation, and Argon Plasma CoagulationOoka K, Farrell J. 1125 Cryoablation of a Duodenal Adenoma With Invasive Carcinoma Refractory to Endoscopic Mucosal Resection, Radiofrequency Ablation, and Argon Plasma Coagulation Gastrointestinal Endoscopy 2017, 85: ab147. DOI: 10.1016/j.gie.2017.03.303.
  • Detection of Advanced Neoplasia in Pancreatic Cysts by Assay of Novel DNA Methylation Markers in Cyst Fluid: A Multicenter Pilot Study: 2016 ACG Fellows-In-Training Award (Biliary/Pancreas Category)Majumder S, Taylor W, Yab T, Berger C, Mahoney D, Aslanian H, Farrell J, Fisher W, Rothberg B, Salem R, Simeone D, Van Buren G, Raimondo M, Chari S, Kisiel J, Topazian M, Ahlquist D. Detection of Advanced Neoplasia in Pancreatic Cysts by Assay of Novel DNA Methylation Markers in Cyst Fluid: A Multicenter Pilot Study: 2016 ACG Fellows-In-Training Award (Biliary/Pancreas Category) The American Journal Of Gastroenterology 2016, 111: s1. DOI: 10.14309/00000434-201610001-00002.
  • DNA Analysis of Pancreatic Cystic Lesions Has Value in Assessing Risk of Future MalignancyFarrell J, Jackson S, Toney N, Gonda T. DNA Analysis of Pancreatic Cystic Lesions Has Value in Assessing Risk of Future Malignancy The American Journal Of Gastroenterology 2016, 111: s139-s140. DOI: 10.14309/00000434-201610001-00298.
  • Sa1245 Impact of Advanced Endoscopy Fellowship Training: A Single-Center Survey AnalysisAhmed A, Aslanian H, Farrell J, Jamidar P. Sa1245 Impact of Advanced Endoscopy Fellowship Training: A Single-Center Survey Analysis Gastrointestinal Endoscopy 2016, 83: ab271. DOI: 10.1016/j.gie.2016.03.404.
  • Su1352 Pathology and Clinical Outcomes of Patients With Recurrent Acute Pancreatitis Undergoing Pancreas Cyst ResectionMuniraj T, Aslanian H, Farrell J, Jamidar P, Mitchell-Richards K, Salem R. Su1352 Pathology and Clinical Outcomes of Patients With Recurrent Acute Pancreatitis Undergoing Pancreas Cyst Resection Gastroenterology 2016, 150: s501. DOI: 10.1016/s0016-5085(16)31726-7.
  • Su1357 Defining Indications for Integrated Molecular Pathology (IMP) in Pancreatic Cystic Neoplasms: Optimizing Management Decisions Based on a Large Clinical Database AnalysisFarrell J, Wong J, Jackson S, Toney N, Finkelstein S. Su1357 Defining Indications for Integrated Molecular Pathology (IMP) in Pancreatic Cystic Neoplasms: Optimizing Management Decisions Based on a Large Clinical Database Analysis Gastroenterology 2016, 150: s502. DOI: 10.1016/s0016-5085(16)31731-0.
  • Tu1468 Evaluation of International Consensus Diagnostic Criteria in the Diagnosis of Autoimmune Pancreatitis: A Single Center North American Cohort StudyMadhani K, Desai H, Wong J, Lee-Felker S, Felker E, Farrell J. Tu1468 Evaluation of International Consensus Diagnostic Criteria in the Diagnosis of Autoimmune Pancreatitis: A Single Center North American Cohort Study Gastroenterology 2016, 150: s910. DOI: 10.1016/s0016-5085(16)33081-5.
  • Classification of Pancreatic LesionsFarrell J. Classification of Pancreatic Lesions 2016, 3-10. DOI: 10.1007/978-3-319-19677-0_1.
  • EUS-Guided Ablation of Pancreatic Cystic Neoplasms: A Large Nationwide Survey Analysis of Practice PatternsRustagi T, Sorser S, Guda N, Aslanian H, Farrell J. EUS-Guided Ablation of Pancreatic Cystic Neoplasms: A Large Nationwide Survey Analysis of Practice Patterns The American Journal Of Gastroenterology 2015, 110: s38. DOI: 10.14309/00000434-201510001-00092.
  • Sa1823 The Preferred Method to Diagnose Small Pancreatic Neuroendocrine Tumors (pNETs) Is by Endoscopic Ultrasound-Guided Fine Needle Aspiration Compared to CT-Guided FNABenhammou J, Al-Jiboury H, Jacob N, Ghassemi K, Pisegna J, Farrell J. Sa1823 The Preferred Method to Diagnose Small Pancreatic Neuroendocrine Tumors (pNETs) Is by Endoscopic Ultrasound-Guided Fine Needle Aspiration Compared to CT-Guided FNA Gastroenterology 2015, 148: s-342. DOI: 10.1016/s0016-5085(15)31139-2.
  • Endoscopic Approaches for Diagnosis of Pancreatic Neuroendocrine TumorsRustagi T, Farrell J. Endoscopic Approaches for Diagnosis of Pancreatic Neuroendocrine Tumors 2014, 95-109. DOI: 10.1007/978-1-4939-1798-3_7.
  • Su1697 A Prospective Double-Blind, Randomized, Sham-Controlled Trial to Evaluate the Effect of a Lead Free Drape on Scatter Radiation Exposure to Endoscopy Staff During ERCP (D-ERCP Study)Muniraj T, Aslanian H, Ho H, Farrell J, Laine L, Jamidar P. Su1697 A Prospective Double-Blind, Randomized, Sham-Controlled Trial to Evaluate the Effect of a Lead Free Drape on Scatter Radiation Exposure to Endoscopy Staff During ERCP (D-ERCP Study) Gastrointestinal Endoscopy 2014, 79: ab370-ab371. DOI: 10.1016/j.gie.2014.02.441.
  • Mo1440 Does Endoscopic Ultrasound Improve Outcome in Surveillance of Non-Resected Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms?Rustagi T, Evans A, Farrell J. Mo1440 Does Endoscopic Ultrasound Improve Outcome in Surveillance of Non-Resected Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms? Gastrointestinal Endoscopy 2014, 79: ab438. DOI: 10.1016/j.gie.2014.02.617.
  • Tu1866 Quality of Life and Cancer Worry of Individuals With Increased Risk for Familial Pancreatic CancerShin E, Goggins M, Schulick R, Petersen G, Hruban R, Cosby H, Topazian M, Syngal S, Farrell J, Lee J, Khashab M, Lennon A, Yeo C, Canto M. Tu1866 Quality of Life and Cancer Worry of Individuals With Increased Risk for Familial Pancreatic Cancer Gastroenterology 2013, 144: s-867. DOI: 10.1016/s0016-5085(13)63223-0.
  • 820 Survival Following Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors: Examining the New 2010 Who ClassificationMoriya T, Donahue T, Hines O, Farrell J, Reber H, Dawson D. 820 Survival Following Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors: Examining the New 2010 Who Classification Gastroenterology 2012, 142: s-1044. DOI: 10.1016/s0016-5085(12)64047-5.
  • 559 Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway ApproachFarrell J, Moughan J, Wong J, Regine W, Scaefer P, Benson A, Macdonald J, Liu X, Yen Y, Lai R, Zheng Z, Bepler G, Guha C, Elsaleh H. 559 Predictive Markers of Gemcitabine Treatment Response in Pancreas Cancer: A Pharmacogenomic Pathway Approach Gastroenterology 2012, 142: s-113. DOI: 10.1016/s0016-5085(12)60424-7.
  • 277 Radial Versus Linear and Second Look Endoscopic Ultrasound (EUS) Improved Detection of Pancreatic Lesions: A Randomized Tandem StudyShin E, Topazian M, Syngal S, Saltzman J, Lee J, Farrell J, Goggins M, Canto M. 277 Radial Versus Linear and Second Look Endoscopic Ultrasound (EUS) Improved Detection of Pancreatic Lesions: A Randomized Tandem Study Gastrointestinal Endoscopy 2012, 75: ab131. DOI: 10.1016/j.gie.2012.04.037.
  • Sa1505 Incremental Value of EUS-FNA Compared With CT/MRI in the Management of Pancreatic Neuroendocrine Tumors (pNETs): Defining the Pivotal Role of EUS-FNAReynolds J, Sedarat A, Oliva I, Tatishchev S, Pisegna J, Farrell J. Sa1505 Incremental Value of EUS-FNA Compared With CT/MRI in the Management of Pancreatic Neuroendocrine Tumors (pNETs): Defining the Pivotal Role of EUS-FNA Gastrointestinal Endoscopy 2012, 75: ab184. DOI: 10.1016/j.gie.2012.04.294.
  • Tu1556 Endoscopic Ultrasound Restaging of Gastric Cancer Following Neoadjuvant Therapy Predicts SurvivalFarrell J, Battish R, Wong J, Wainberg Z, Eilber F. Tu1556 Endoscopic Ultrasound Restaging of Gastric Cancer Following Neoadjuvant Therapy Predicts Survival Gastrointestinal Endoscopy 2012, 75: ab445. DOI: 10.1016/j.gie.2012.03.1202.
  • Sa1542 Evolving Role of Endoscopic Ultrasound Before Surgery After Medical Down-Staging of Pancreaticobiliary CancersPaul N, Donahue T, Wong J, Tomlinson J, Hines O, Reber H, Farrell J. Sa1542 Evolving Role of Endoscopic Ultrasound Before Surgery After Medical Down-Staging of Pancreaticobiliary Cancers Gastrointestinal Endoscopy 2012, 75: ab196. DOI: 10.1016/j.gie.2012.04.331.
  • Changing Trends in Pancreatic Cyst Pathology 1995 to 2010: Does Endoscopic Ultrasonography Improve Preoperative Selection?Yeh J, Singh I, Donahue T, Tomlinson J, Dawson D, Hines O, Reber H, Farrell J. Changing Trends in Pancreatic Cyst Pathology 1995 to 2010: Does Endoscopic Ultrasonography Improve Preoperative Selection? Gastroenterology 2011, 140: s-711. DOI: 10.1016/s0016-5085(11)62953-3.
  • Su1377 Initial Experience With a Novel Endoscopic Ultrasound Guided Biopsy (EUSCB) Core Needle Compared With Standard Fine Needle Aspiration (EUSFNA). A Formal Prospective Tandem Comparative Study in Pancreatic MassesBattish R, Wong J, Farrell J. Su1377 Initial Experience With a Novel Endoscopic Ultrasound Guided Biopsy (EUSCB) Core Needle Compared With Standard Fine Needle Aspiration (EUSFNA). A Formal Prospective Tandem Comparative Study in Pancreatic Masses Gastrointestinal Endoscopy 2011, 73: ab247-ab248. DOI: 10.1016/j.gie.2011.03.430.
  • Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic CancerFarrell J, Wong J, Donahue T, Rao J. Su1384 Development and Validation of an EUS-FNA-Based Predictive Marker of Gemcitabine Response in Pancreatic Cancer Gastrointestinal Endoscopy 2011, 73: ab249-ab250. DOI: 10.1016/j.gie.2011.03.437.
  • 415g: Screening for Familial Pancreatic Neoplasia:a Prospective, Multicenter Blinded Study of EUS, CT, and Secretin-MRCP (The NCI-Spore Lustgarten Foundation Cancer of the Pancreas CAPS 3 Study)Canto M, Schulick R, Kamel I, Fishman E, Topazian M, Takahashi N, Lee J, Tamm E, Vikram R, Syngal S, Saltzman J, Mortele K, Farrell J, Margolis D, Zhang Z, Petersen G, Hruban R, Goggins M. 415g: Screening for Familial Pancreatic Neoplasia:a Prospective, Multicenter Blinded Study of EUS, CT, and Secretin-MRCP (The NCI-Spore Lustgarten Foundation Cancer of the Pancreas CAPS 3 Study) Gastrointestinal Endoscopy 2010, 71: ab119. DOI: 10.1016/j.gie.2010.03.058.
  • Chapter 100 Digestion and Absorption of Nutrients and VitaminsFarrell J. Chapter 100 Digestion and Absorption of Nutrients and Vitamins 2010, 1695-1733.e8. DOI: 10.1016/b978-1-4160-6189-2.00100-1.
  • Salivary biomarkers for pancreatic cancer detectionWong D, Zhang L, Farrell J, Zhou H, Elashoff D, Gao K, Paster B. Salivary biomarkers for pancreatic cancer detection Journal Of Clinical Oncology 2009, 27: 4630-4630. DOI: 10.1200/jco.2009.27.15_suppl.4630.
  • 163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic CancerFarrell J, Garcia M, Liu X, Ammar A, Regine W, Abrams R, Elsaleh H. 163 Ribonulceotide Reductase M2 (RRM2): Predictive Marker of Response to Gemcitabine in Pancreatic Cancer Gastroenterology 2009, 136: a-32. DOI: 10.1016/s0016-5085(09)60146-3.
  • Endoscopic Ultrasound Restaging of Gastric Cancer Following Neoadjuvant TherapyFarrell J, Eilber F. Endoscopic Ultrasound Restaging of Gastric Cancer Following Neoadjuvant Therapy Gastrointestinal Endoscopy 2009, 69: ab245. DOI: 10.1016/j.gie.2009.03.617.
  • Validation of Randomization Based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial DesignFarrell J, Bae K, Fromm M, Regine W, Abrams R, Safran H, Hoffman J, Dicker A, Elsaleh H. Validation of Randomization Based on Patient Genotype Results from RTOG 9704 Trial in Pancreatic Cancer and Implications for Future Trial Design International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s15. DOI: 10.1016/j.ijrobp.2008.06.799.
  • M2031 Tumor-Associated Macrophages (TAMS) Are Poor Prognostic Indicators in Pancreatic CancerFarrell J, Garcia M, Dicker A, Guha C, Elsaleh H. M2031 Tumor-Associated Macrophages (TAMS) Are Poor Prognostic Indicators in Pancreatic Cancer Gastroenterology 2008, 134: a-454. DOI: 10.1016/s0016-5085(08)62124-1.
  • W1418 Are We Performing Fewer Resections of Low Risk Pancreatic Cysts? Time Trends and Analysis from a Large CohortWeinberg B, Farrell J, Tang R, Dawson D, Reber H, Hines O, Tomlinson J, Spiegel B. W1418 Are We Performing Fewer Resections of Low Risk Pancreatic Cysts? Time Trends and Analysis from a Large Cohort Gastroenterology 2008, 134: a-700. DOI: 10.1016/s0016-5085(08)63268-0.
  • Chapter 32 ERCP for the Acute and Chronic Complications of Pancreatic SurgeryFarrell J, Carr-Locke D. Chapter 32 ERCP for the Acute and Chronic Complications of Pancreatic Surgery 2008, 347-355. DOI: 10.1016/b978-1-4160-4271-6.50037-x.
  • EVALUATION OF THE CONSENSUS GUIDELINES FOR THE OPERATIVE MANAGEMENT OF SIDE BRANCH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF PANCREASTang R, Weinberg B, Dawson D, Chaudhari V, Raman S, Reber H, Hines O, Tomlinson J, Farrell J. EVALUATION OF THE CONSENSUS GUIDELINES FOR THE OPERATIVE MANAGEMENT OF SIDE BRANCH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF PANCREAS Pancreas 2007, 35: 430-431. DOI: 10.1097/01.mpa.0000297797.88293.13.
  • HUMAN ENT1 IS PREDICTIVE OF RESPONSE IN PATIENTS WITH PANCREATIC CANCER TREATED WITH GEMCITABINEFarrell J, Garcia M, Lai R, Ammar A, Regine W, Abrams R, Benson A, Macdonald J, Cass C, Elsaleh H, Mackey J. HUMAN ENT1 IS PREDICTIVE OF RESPONSE IN PATIENTS WITH PANCREATIC CANCER TREATED WITH GEMCITABINE Pancreas 2007, 35: 401-402. DOI: 10.1097/01.mpa.0000297698.99488.6c.
  • IDENTIFICATION OF UNIQUE DIFFERENTIAL PROTEOMIC BIOMARKERS IN PANCREATIC CYSTIC NEOPLASM FLUIDFarrell J, Souda P, Hasanzadeh B, Whitelegge J, Faull K. IDENTIFICATION OF UNIQUE DIFFERENTIAL PROTEOMIC BIOMARKERS IN PANCREATIC CYSTIC NEOPLASM FLUID Pancreas 2006, 33: 459. DOI: 10.1097/00006676-200611000-00078.
  • PREDICTIVE MARKERS OF TREATMENT RESPONSE TO 5-FU AND GEMCITABINE IN PANCREATIC CANCERFarrell J, Lai R, Winter K, Van Rijnsoever M, Regine W, Schaeffer P, Benson A, Macdonald J, Willett C, Mackey J, Elsaleh H. PREDICTIVE MARKERS OF TREATMENT RESPONSE TO 5-FU AND GEMCITABINE IN PANCREATIC CANCER Pancreas 2006, 33: 459. DOI: 10.1097/00006676-200611000-00079.
  • Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC)Farrell J, Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Chang K, Macko J, Hecht J. Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC) Endoscopy 2006, 39 DOI: 10.1055/s-2006-947607.
  • Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC)Farrell J, Senzer N, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Chang K, Macko J, Hecht J. Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC) Endoscopy 2006, 39 DOI: 10.1055/s-2006-947613.
  • Endoscopic Ultrasound (EUS)-guided Fine Needle Aspiration (FNA) Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared to Computerized Tomography (CT)-guided FNAGhassemi K, Pisegna J, Farrell J. Endoscopic Ultrasound (EUS)-guided Fine Needle Aspiration (FNA) Accurately Diagnoses Smaller Pancreatic Neuroendocrine Tumors Compared to Computerized Tomography (CT)-guided FNA Endoscopy 2006, 39 DOI: 10.1055/s-2006-947636.
  • Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (PTA) Guided Intratumoral TNFerade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC)Farrell J, Senzer N, Hecht J, Hanna N, Chung T, Nemunaitis J, Rosemurgy A, Javle M, Reid T, Posner M, Macko J, Chang K. Long-Term Data for Endoscopic Ultrasound (EUS) and Percutanous (PTA) Guided Intratumoral TNFerade Gene Delivery Combined with Chemoradiation in the Treatment of Locally Advanced Pancreatic Cancer (LAPC) Gastrointestinal Endoscopy 2006, 63: ab93. DOI: 10.1016/j.gie.2006.03.071.
  • 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) POLYMORPHISM AND PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIALFarrell J, Winter K, Van Rijnsoever M, Regine W, Abrams R, Safran H, Hoffman J, Schaeffer P, Mohiuddin M, Macdonald J, Benson A, Willett C, Elsaleh H. 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) POLYMORPHISM AND PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL Pancreas 2005, 31: 440. DOI: 10.1097/01.mpa.0000193664.86654.55.
  • THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIALFarrell J, Winter K, Van Rijnsoever M, Regine W, Abrams R, Safran H, Hoffman J, Schaeffer P, Mohiuddin M, Macdonald J, Benson A, Willett C, Elsaleh H. THYMIDYLATE SYNTHASE AND THYMIDINE PHOSPHORYLASE: PROTEIN EXPRESSION AND GENOTYPE IN PANCREATIC CANCER: RESULTS FROM THE RTOG 9704 PROSPECTIVE RANDOMIZED ADJUVANT TREATMENT TRIAL Pancreas 2005, 31: 439-440. DOI: 10.1097/01.mpa.0000193663.09525.af.
  • ENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION (EUS-FNI) OF A NOVEL GENE TRANSFER THERAPY AGAINST PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCEFarrell J, Macko J, Hecht J. ENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION (EUS-FNI) OF A NOVEL GENE TRANSFER THERAPY AGAINST PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE Pancreas 2005, 31: 440. DOI: 10.1097/01.mpa.0000193665.94277.73.
  • A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI)Chang K, Senzer N, Chung T, Hecht J, Vogel S, Rosemurgy A, Nemunaitis J, Gibbs J, Javle M, Reid T, Macko J, Kessler P, Posner M, Farrell J, Grundy L, Soetikno R, Waxman I, Hanna N. A Novel Gene Transfer Therapy Against Pancreatic Cancer (TNFerade) Delivered by Endoscopic Ultrasound (EUS) and Percutaneous Guided Fine Needle Injection (FNI) Gastrointestinal Endoscopy 2004, 59: p92. DOI: 10.1016/s0016-5107(04)00470-5.
  • The cost-effectiveness of colonic stenting in the management of acute malignant colonic obstructionTargownik L, Farrell J, Spiegel B, Dulai G, Gralnek I. The cost-effectiveness of colonic stenting in the management of acute malignant colonic obstruction The American Journal Of Gastroenterology 2003, 98: s120. DOI: 10.1111/j.1572-0241.2003.08092.x.
  • Endoscopic mucosal resection for gastric neoplasmsFarrell J, Brugge W. Endoscopic mucosal resection for gastric neoplasms Techniques And Innovations In Gastrointestinal Endoscopy 2002, 4: 34-41. DOI: 10.1053/tgie.2002.31949.
  • Sclerosing pancreatocholangitis: A reversible variant of PSCFarrell J, Kelsey P, Graeme-Cook F, Chung R. Sclerosing pancreatocholangitis: A reversible variant of PSC Gastroenterology 2000, 118: a420. DOI: 10.1016/s0016-5085(00)83794-4.

Clinical Trials